AMARIN CORP PLC\UK (AMRN) Form 10-Q — Oct 28, 2026
Amarin reported Q3 2026 total revenue of $39.6 million, down roughly 20% from $49.7 million a year earlier, as VASCEPA product revenue fell to $36.9 million from $48.6 million. The company was nearly breakeven in the quarter, posting net income of $245 thousand versus a net loss of $7.7 million in Q3 2025, helped by cost cutting that cut SG&A and eliminated restructuring charges. For the first nine months of 2026, Amarin still posted a net loss of $17.9 million on revenue of $126.9 million, with $323 million in combined cash, equivalents, and short-term investments at quarter end.
Key figures
- Eps
- 0
- Revenue
- 39550000
- Net Income
- 245000
- Revenue Yoy
- -20.4%
- Cash Position
- 156512000
- Gross margin q3
- 16181000
- Q3 product revenue
- 36890000
- Short term investments
- 166867000
- Nine month total revenue
- 126893000
- Q3 product revenue prior year
- 48558000
- Shares outstanding weighted basic
- 417766000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.